BioSimilar – Policy & Medicine

FDA Seeking Comments on Draft Guidance on Biosimilar Drugs and Reference Products

Biosimilar Data Presented at AAO 2022

HHS OIG Report Finds that Medicare Could Save Money with Increased Biologic Use

FDA Updates Final Guidance on Biosimilar Development

Opinion Editorial: Why Should We Rescue The Legislative Intent Of The BPCIA?

FDA Releases Draft Question and Answers Guidance on Interchangeable Products

AbbVie Notches Major Victory in Antitrust Suit

Biosimilars Could Save Taxpayers Billions

FDA Releases Draft Guidance on Biosimilar Review

FDA and FTC Join Forces on Biosimilar Marketing